Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05887609 | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | recruiting | Phase 2 | 53 | University of Colorado, DenverOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07139977 | Study of EV for Recurrent Endometrial Carcinoma(EV-4-EC) | recruiting | Phase 2 | 12 | William BradleyOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07322094 |
| CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer |
| recruiting |
| Phase 1 / Phase 2 |
| 60 |
| TORL Biotherapeutics, LLCINDUSTRY |
| 1 |
| Jul 13, 2026 |
| clinicaltrials |
| NCT07693452 | Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms | recruiting | Phase 2 | 15 | University of California, IrvineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07048314 | Stem Cells for Erectile Dysfunction Post RALP | recruiting | Phase 1 / Phase 2 | 40 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03972657 | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | recruiting | Phase 1 / Phase 2 | 345 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04774419 | Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07689656 | A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04175431 | Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | recruiting | Phase 2 | 100 | University of WashingtonOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05127824 | Autologous Dendritic Cell Vaccine in Kidney Cancer | recruiting | Phase 2 | 42 | Jodi MaranchieOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06526299 | Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease | recruiting | Phase 2 | 51 | University of WashingtonOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07552168 | INSPIRE: INnovative SABR for Prostate Cancer All IREland | recruiting | Phase 2 | 136 | Cancer Trials IrelandNETWORK | 2 | Jul 6, 2026 | clinicaltrials |
| NCT07087158 | A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma | recruiting | Phase 2 | 30 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06401980 | Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | recruiting | Phase 2 | 162 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07125391 | Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer | recruiting | Phase 2 | 136 | Bai-Rong XiaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07313241 | Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)((RANGER)) | recruiting | Phase 2 | 68 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05952453 | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro | recruiting | Phase 2 | 20 | University of Alabama at BirminghamOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06568562 | XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer(PRO-XL) | recruiting | Phase 2 | 32 | University of UtahOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT07672860 | Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors(PURIFY) | recruiting | Phase 2 | 146 | Jinling Hospital, ChinaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03832361 | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer | recruiting | Phase 2 | 50 | Alessandro SantinOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | recruiting | Phase 2 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06457919 | A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06835972 | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 / Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04947254 | Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06533644 | A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 91 | Syncromune, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03675893 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07110038 | DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma | recruiting | Phase 2 | 25 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05071937 | ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer | recruiting | Phase 2 | 33 | Alexander B Olawaiye, MDOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05538091 | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | recruiting | Phase 2 | 48 | Ronald BuckanovichOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06922318 | The COSMYC Trial (COmbined Suppression of MYC) | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07407582 | Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) | recruiting | Phase 1 / Phase 2 | 25 | University of ArizonaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07635238 | A Study of Lower Dose Radiation Therapy for People With Prostate Cancer | recruiting | Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04055649 | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | recruiting | Phase 2 | 62 | Ira WinerOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05790213 | Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation | recruiting | Phase 2 | 57 | University of ChicagoOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06392295 | PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer(OCEAN) | recruiting | Phase 2 | 34 | University of MiamiOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07027124 | Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer | recruiting | Phase 2 | 40 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06434350 | Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) | recruiting | Phase 1 / Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | recruiting | Phase 2 | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 13, 2026source: clinicaltrials